Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

Recruiting now · Phase 3

Conditions studied: Acute Myeloid Leukemia

In brief

This research focuses on a prospective, randomized, controlled trial of "Interferon-alpha as maintenance therapy for favorable-risk acute myeloid leukemia." By fully utilizing prospective, randomized, controlled clinical trial and studying the negative conversion of MRD and the survival of favorable-risk AML patients, it aims to explore the efficacy and safety of Interferon-alpha in the maintenance treatment of favorable-risk AML and identify effective measures to prevent relapse, thereby improving the survival of favorable-risk AML patients. The primary endpoint is the negative conversion of MRD at 6 months. The secondary endpoints include the 2-year cumulative incidence of relapse, 2-year event-free survival (EFS), 2-year overall survival (OS), and safety.

Key facts

Study ID

NCT06802718

Run by

Peking University People's Hospital

People needed

96

Starts

2023-01-01

Expected to finish

2026-12-01

Last updated by the study team

2025-01-31

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18-70 years old (including 18 and 70 years old) with newly diagnosed favorable-risk AML (2022 ELN risk group classification).
• Achieved CR1 after 1-2 cycles of standard chemotherapy.
• Completed 4-6 cycles of consolidation chemotherapy (including at least 2 cycles of high-dose Cytarabine HDAC regimem).
• At the end of consolidation treatment, bone marrow examination confirmed in CR1, flow cytometry MRD negative, but molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by > 3 log, but still detectable.
• Performance status score of 0-2 (ECOG).
• Liver function: ALT and AST ≤ 2.5 times the upper limit of normal, bilirubin ≤ 2 times the upper limit of normal.
• Kidney function: Creatinine ≤ 1.5 times the upper limit of normal.

You may not qualify if…

• Acute promyelocytic leukemia (APL).
• AML with normal karyotype and bZIP intramolecular mutations in CEBPA.
• ≥ CR2 status.
• Patients strongly demanding transplantation, and with indications for transplantation but not eligible for transplantation.
• Uncontrolled active infection.
• Severe organ dysfunction.
• Pregnancy.
• Unwillingness to undergo interferon treatment.
• Previous hyperthyroidism or hypothyroidism.
• Participation in other clinical trials within one month.

Where it is running

• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.